Cipla announced that the USFDA conducted a routine cGMP inspection at its API manufacturing facility in Virgonangar, Bengaluru, from 15 July 2019 to 19 July 2019.
The inspection ended with 7 observations, none of which were repeat or related to data integrity.
The Company will respond to the agency within the stipulated timeline.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)